Neumora Therapeutics公布了其候选药物Nmra-215的毒理学研究结果,表现良好。公司计划于2026年将该药物推向临床开发的下一阶段。
Neumora Therapeutics公布了其候选药物Nmra-215的毒理学研究结果,表现良好。公司计划于2026年将该药物推向临床开发的下一阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.